NCM
ANIK icon

Nantahala Capital Management’s Anika Therapeutics ANIK Stock Holding History

Nantahala Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,961
Closed -$197K – 155
2025
Q3 		$197K Buy
+20,961
New +$200K 0.01% 150

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nantahala Capital Management's ANIK Position: Q4 2025 in Review

Nantahala Capital Management sold out of Anika Therapeutics (ANIK) in Q4 2025, closing a stake of 20,961 shares — an estimated $197K sold.

Nantahala Capital Management first reported a position in ANIK in Q3 2025 and held it in 1 quarter. The position peaked at $197K in Q3 2025. 126 funds tracked by Wall St. Rank hold ANIK as of Q4 2025.

  • Nantahala Capital Management reported no remaining Anika Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 20,961 Anika Therapeutics shares in Q4 2025, an estimated $197K.
  • Nantahala Capital Management first reported a position in Anika Therapeutics in Q3 2025 and held it in 1 quarter.
  • Nantahala Capital Management's Anika Therapeutics position peaked at $197K in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.